Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.76 |
| ▸ | CNR1 | P21554 | 1/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.44 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296083 | 1.00 | TDP1 (0.79) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL296084 | 1.00 | TDP1 (0.79) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL1073320 | 0.91 | TDP1 (0.84) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL4991907 | 0.91 | TDP1 (0.84) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL1073323 | 0.91 | TDP1 (0.84) | TDP1LMNAADRA2ACNR1ATM | |
| Phenothrin SCHEMBL24119149 | 0.89 | TDP1 (1.00) | TDP1LMNAADRA2ACNR1ATM | |
| Phenothrin SCHEMBL13062899 | 0.89 | TDP1 (1.00) | TDP1LMNAADRA2ACNR1ATM | |
| Phenothrin SCHEMBL13062903 | 0.89 | TDP1 (1.00) | TDP1LMNAADRA2ACNR1ATM | |
| Phenothrin SCHEMBL8649333 | 0.89 | TDP1 (1.00) | TDP1LMNAADRA2ACNR1ATM | |
| Phenothrin SCHEMBL2963269 | 0.89 | TDP1 (1.00) | TDP1LMNAADRA2ACNR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1683782-B1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO (JP) | 2012-03-14 | — | — | EP | disclosed |
| EP-1120402-B1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO (JP) | 2008-06-25 | — | — | EP | disclosed |
| EP-1683782-A2 | Chiral copper complex and production processes thereof and using the same | Sumitomo Chemical Company, Limited (JP) | 2006-07-26 | — | — | EP | disclosed |
| EP-1683783-A2 | Chiral copper complex and production processes thereof and using the same | Sumitomo Chemical Company, Limited (JP) | 2006-07-26 | — | — | EP | disclosed |
| US-20050090684-A1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO., LTD. | 2005-04-28 | — | — | US | disclosed |
| US-6670500-B2 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-12-30 | — | — | US | disclosed |
| US-20020004618-A1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-10 | — | — | US | disclosed |
| EP-1120402-A2 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090684-A1 | Chiral copper complex and production processes thereof and using the same | SOD1, CYP1A1, NFXL1 | TDP1 4523/4885LMNA 4567/4885ADRA2A 1258/4885 |
| US-20020004618-A1 | Chiral copper complex and production processes thereof and using the same | SOD1, XDH, NFXL1 | TDP1 3929/4885LMNA 4559/4885ADRA2A 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.